Research Topics
Species | Michael WangSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Use of bortezomib in B-cell non-Hodgkin's lymphomaMichael Wang
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030 4009, USA
Expert Rev Anticancer Ther 6:983-91. 2006..Mantle cell lymphoma was significantly more sensitive to bortezomib than other non-Hodgkin's lymphomas. Bortezomib may have far-reaching potential in the treatment of B-cell non-Hodgkin's lymphoma...- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureMichael Wang
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 112:4445-51. 2008..Studies were registered at http://www.clinicaltrials.gov under NCT00056160 and NCT00424047... - Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Br J Haematol 150:200-8. 2010..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL... - Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
Br J Haematol 151:47-53. 2010..In particular, there was no pulmonary or neurological dose-limiting toxicity, showing that bortezomib can be safely combined with R-HyperCVAD and R-M/A... - Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphomaMichael Wang
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 113:2734-41. 2008.... - Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosisYuhuan Zheng
Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 114:3625-8. 2009..Thus, our results indicate that Mvarphis may contribute to myeloma cell survival and resistance to chemotherapeutic treatment in vivo... - Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myelomaJianfei Qian
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 114:3880-9. 2009.... - Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivoLuhong Sun
Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Leuk Res 36:363-8. 2012..Our results demonstrate that ATI and BTZ confer significant therapeutic effects in MCL in vitro and in vivo and should therefore be investigated in a clinical trial in patients with relapsed or refractory MCL... - Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialMuzaffar H Qazilbash
Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 14:1401-7. 2008..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM... - Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myelomaUday Popat
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 15:718-23. 2009..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients... - High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera
Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 23:7013-23. 2005..To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL)... - Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosisJing Yang
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Cell 12:252-65. 2007..CRP also enhanced myeloma cell secretion of IL-6 and synergized with IL-6 to protect myeloma cells from chemotherapy drug-induced apoptosis. Thus, our results implicate CRP as a potential target for cancer treatment... - Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivoZhengzi Qian
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Leuk Res 35:380-6. 2011..Importantly, the combination of LEN and DEX delayed the tumor growth and improved the survival of MCL-bearing mice. The results support the use of the LEN and DEX combination as a new therapeutic regimen in clinical trials of MCL... - Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomideChad C Bjorklund
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Biol Chem 286:11009-20. 2011.... - A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphomaMichael Wang
Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:2154-60. 2008..To establish a severe combined immunodeficient (SCID)-hu in vivo mouse model of human primary mantle cell lymphoma (MCL) for the study of the biology and novel therapy of human MCL... - Targeting cell surface ?2 -microglobulin by pentameric IgM antibodiesYabing Cao
Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Br J Haematol 154:111-21. 2011..Thus, we developed and validated the efficacy of anti-?(2) M IgM mAbs that may be utilized in the clinical setting and showed that IgM anti-?(2) M mAbs may be more potent than IgG mAbs at inducing tumour apoptosis... - Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber
Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
N Engl J Med 357:2133-42. 2007..Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma... - Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivoLiang Zhang
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
Am J Hematol 84:553-9. 2009.... - Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid raftsJing Yang
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:3028-35. 2007..Thus, this study further defines the tumoricidal mechanism of the mAbs and provides strong evidence to support the potential of these mAbs as therapeutic agents for myeloma... - Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
J Clin Oncol 23:667-75. 2005..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma... - Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 27:5213-8. 2009..This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL)... - Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myelomaQaiser Bashir
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
Am J Hematol 87:272-6. 2012..Further studies should be conducted in carefully designed clinical trials in this patient population. Am. J. Hematol., 2012. © 2011 Wiley Periodicals, Inc... - Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myelomaGaurav C Parikh
Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, TX 77030, USA
Biol Blood Marrow Transplant 15:812-6. 2009..In this analysis, a melphalan (Mel) dose of 200 mg/m(2) was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM)... - Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphomaAnas Younes
Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Eur J Cancer 42:2976-81. 2006..Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule... - Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphomaMichael Wang
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:3231-41. 2008..There is a lack of research on ethnic disparities in survival among patients with non-Hodgkin lymphoma (NHL), although these disparities have been documented for patients with many other tumors... - Thalidomide-dexamethasone as primary therapy for advanced multiple myelomaMichael Wang
University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
Am J Hematol 79:194-7. 2005..Thalidomide-dexamethasone was useful for these patients with advanced disease because of the high response rate and acceptable survival, with a low frequency of serious complications... - HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaRichard J Jones
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Blood 118:4140-9. 2011..These findings provide a framework for translation of the rational combination of an HDM-2 and RNR inhibitor to the clinic for patients with relapsed wtp53 MCL... - Bortezomib-resistant nuclear factor ?B expression in stem-like cells in mantle cell lymphomaHyun Joo Jung
Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Exp Hematol 40:107-18.e2. 2012..Given that the NF-?B expression in MCL-ICs is resistant to bortezomib, it will be important to find alternative therapeutic strategies to inhibit NF-?B expression... - Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaJianfei Qian
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:1587-94. 2007..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM... - Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathwaysMichael Wang
Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 109:5455-62. 2007..Cell apoptosis was induced mainly via activation of the AIF pathway. These results support the use of atiprimod as a potential agent in MCL chemotherapy... - Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaSally A Hunsucker
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
Br J Haematol 152:579-92. 2011..These studies provide a rationale for translation of siltuximab into the clinic in combination with melphalan-based therapies... - Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004Yuhong Zhou
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:791-8. 2008..The purpose of the current study was to examine the incidence of MCL over a period of 13 years and to identify the factors associated with the incidence patterns... - Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian
The University of Texas M.D. Anderson Cancer Center, Box 429, 1515 Holcombe Blvd, Houston, TX 77030, USA
Semin Hematol 40:3-7. 2003..Our program of thalidomide/dexamethasone was a safe and effective combination for patients with resistant or relapsing disease, or as consolidation of partial remission after intensive therapy... - Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myelomaYvonne A Efebera
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Biol Blood Marrow Transplant 16:1122-9. 2010..The use of RIC allo-HSCT earlier in the course of the disease may offer the greatest benefit... - Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphomaAmar Safdar
Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Infect Dis 194:1394-7. 2006..For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine... - Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohortNidhi Rohatgi
Division of Epidemiology, School of Public Health, University of Texas Health Science Center, Houston, TX 77030, USA
Am J Clin Oncol 30:540-8. 2007..To assess the patterns of chemotherapy use for patients with multiple myeloma and to determine if chemotherapy is effective in prolonging survival outside the clinical trial settings... - Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytesJinsheng Weng
Department of Lymphoma and Myeloma, Stem Cell Transplantation and Cellular Therapy, and Center for Cancer Immunology Research, MD Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 17:5945-52. 2011..However, epitopes derived from Id that stimulate human CD8(+) T-cell immunity are incompletely characterized... - Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivoJianguo Wen
Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin MS205, Houston, TX 77030, USA
Mol Cancer Ther 10:148-58. 2011..Our findings indicate that Cetrorelix induces cytotoxicity in myeloma cells through various mechanisms and provide a rationale for investigating Cetrorelix for the treatment of MM... - Feasibility of autologous hematopoietic stem cell transplant in patients aged ?70 years with multiple myelomaQaiser Bashir
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Leuk Lymphoma 53:118-22. 2012..These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ?70 years and age alone should not be an exclusion criterion for auto HCT... - Effect of long-term storage in TRIzol on microarray-based gene expression profilingWencai Ma
The Myeloma Tissue and Leukemia Satellite Sample Banks, Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
Cancer Epidemiol Biomarkers Prev 19:2445-52. 2010.... - International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)S Giralt
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Leukemia 23:1904-12. 2009..The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions... - Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cellsJohn L Clifford
Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Mol Cancer Ther 2:453-9. 2003..Furthermore, we propose that these dnSTAT2-expressing cells provide a novel in vitro model for the study of type I IFN action in human skin cells... - Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemiaEllen C Mullen
University of Texas M D Anderson Cancer Center, Houston, USA
Clin J Oncol Nurs 11:87-95. 2007..Although hyperviscosity syndrome is not one of the most common conditions, when it does occur, oncology nurses play a critical role in patients' assessment and care... - Prospective isolation of clonogenic mantle cell lymphoma-initiating cellsZheng Chen
Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases IMM, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Stem Cell Res 5:212-25. 2010.... - Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplantMuzaffar H Qazilbash
Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 13:1066-72. 2007..02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma... - Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang
The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
J Clin Oncol 22:4095-102. 2004..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL... - Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignanciesJing Yang
Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Cell 10:295-307. 2006..Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies... - Outcomes in lymphoma patients with obstructive jaundice: a cancer center experienceWilliam A Ross
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Dig Dis Sci 55:3271-7. 2010..Little information is available to guide clinicians on the optimal approach to managing obstructive jaundice in lymphoma patients... - Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang
Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
Br J Haematol 138:502-5. 2007..The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon... - Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastasesMartin Majer
Multidisciplinary Melanoma Program, Huntsman Cancer Institute, Salt Lake City, Utah, USA
Cancer 110:1329-37. 2007.... - Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyondYuhong Zhou
Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Am J Hematol 83:144-9. 2008..A Phase I/II study is ongoing to determine the maximum tolerated dose (MTD) and the efficacy of lenalidomide in combination with Rituximab for relapsed/refractory MCL. This review summarizes the latest and exciting advances in MCL... - Current status and future directions in the treatment of multiple myelomaJian Hou
Chin Med J (Engl) 120:1651-4. 2007 - A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedingsEdward A Stadtmauer
Hematology/Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Clin Adv Hematol Oncol 5:7-19, quiz 21-2. 2007 - Modulation of immune system function by measles virus infection. II. Infection of B cells leads to the production of a soluble factor that arrests uninfected B cells in G0/G1Michael Wang
Division of Hematology/Oncology/Bone-Marrow Transplantation, The Children's Hospital Denver, Colorado, USA
Viral Immunol 16:45-55. 2003.... - Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS)Wolfram E Samlowski
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
Cancer 109:1855-62. 2007..We performed a retrospective analysis of our institutional experience of multimodality treatment utilizing linear accelerator (Linac)-based stereotactic radiosurgery (SRS)... - Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogsDanielle Euler
Department of Pharmaceutical Research and Development, Merck and Co, Inc, West Point, PA 19486, USA
Int J Pharm 275:19-27. 2004..Regional absorption results suggested that the compound was absorbed along the gastrointestinal tract in Beagle dogs, however colonic absorption appeared to be reduced by slower dissolution... - The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus StatementM A Hussein
Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
Leukemia 22:1479-84. 2008 - Bim and Bcl-2 mutually affect the expression of the other in T cellsTrine N Jorgensen
Integrated Department of Immunology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
J Immunol 179:3417-24. 2007..These mutual effects occur even if Bcl-2 is induced acutely. Thus these two proteins control the expression of the other, at either the protein or mRNA level...